From GlobeNewswire: 2025-06-16 23:38:00

Jyong Biotech Ltd. in Taiwan priced its initial public offering of 2,666,667 Ordinary Shares at $7.50 per share, expecting to raise $20 million. The company plans to list on Nasdaq under the ticker symbol “MENS” on June 17, 2025. Proceeds will fund Phase III trials and new drug applications, with a breakdown of 40% for MCS-2 trials, 25% for earlier phase trials, and 10% for PCP trials. The Offering is conducted on a firm commitment basis and granted the underwriters an Over-Allotment Option. Interested investors can obtain a prospectus from Joseph Stone Capital, LLC.

Jyong Biotech Ltd., a biotechnology company specializing in plant-derived drugs for urinary system diseases, plans to use IPO proceeds for Phase III and II trials, clinical trials, and general corporate purposes. The Offering is conducted on a firm commitment basis with Joseph Stone Capital, LLC as the sole underwriter. Interested investors can obtain a prospectus from Joseph Stone Capital, LLC. The Offering is expected to close on June 18, 2025, subject to customary closing conditions. The net proceeds will fund various drug trials and applications, positioning the company for growth and innovation in the biotech sector.



Read more at GlobeNewswire: Jyong Biotech Ltd. Announces Pricing of $20 Million Initial